Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2020 / Article
Special Issue

Using Reactive Oxygen and Nitrogen Species in Cancer Treatment

View this Special Issue

Research Article | Open Access

Volume 2020 |Article ID 5167292 | https://doi.org/10.1155/2020/5167292

Wangta Liu, Chang-Yi Wu, Mei-Jei Lu, Yung-Jen Chuang, Eing-Mei Tsai, Steve Leu, I-Ling Lin, Chih-Jan Ko, Chien-Chih Chiu, Wen-Tsan Chang, "The Phenoxyphenol Compound 4-HPPP Selectively Induces Antiproliferation Effects and Apoptosis in Human Lung Cancer Cells through Aneupolyploidization and ATR DNA Repair Signaling", Oxidative Medicine and Cellular Longevity, vol. 2020, Article ID 5167292, 14 pages, 2020. https://doi.org/10.1155/2020/5167292

The Phenoxyphenol Compound 4-HPPP Selectively Induces Antiproliferation Effects and Apoptosis in Human Lung Cancer Cells through Aneupolyploidization and ATR DNA Repair Signaling

Guest Editor: Nagendra K. Kaushik
Received18 Feb 2019
Revised04 Oct 2019
Accepted10 Oct 2019
Published08 Jan 2020

Abstract

Lung cancer is a leading cause of cancer death worldwide, and non-small-cell lung cancer (NSCLC) accounts for 85% of lung cancer, which is highly metastatic, leading to the poor survival rate of patients. We recently reported that 4-[4-(4-hydroxyphenoxy)phenoxy]phenol (4-HPPP), a phenoxyphenol, exerts antihepatoma effects by inducing apoptosis and autophagy. In this study, we further examined the effect of 4-HPPP and its analogs on NSCLC cells. Colony formation assays showed that 4-HPPP exerts selective cytotoxicity against NSCLC H1299 cells; furthermore, the inhibitory effect of 4-HPPP on the proliferation and migration of NSCLC cells was validated using an in vivo zebrafish-based tumor xenograft assay. The flow cytometry-based dichlorofluorescein diacetate (DCF-DA) assays indicated that 4-HPPP caused an increase in reactive oxygen species (ROS) in NSCLC cells, and Western blot assays showed that the major ROS scavenging enzymes superoxide dismutases- (SODs-) 1/2 were upregulated, whereas peroxidase (PRX) was downregulated. Furthermore, 4-HPPP caused both aneuploidization and the accumulation of γH2AX, a sensor of DNA damage, as well as the activation of double-strand break (DSB) markers, especially Ataxia-telangiectasia-mutated and Rad3-related (ATR) in NSCLC cells. Our present work suggests that the antiproliferative effects of 4-HPPP on lung cancer cells could be due to its phenoxyphenol structure, and 4-HPPP could be a candidate molecule for treating NSCLC by modulating ROS levels and lowering the threshold of polyploidy-specific cell death in the future.

1. Introduction

Lung cancer has a high incidence and is the leading cause of cancer-associated deaths in both males and females [13]. Non-small-cell lung carcinoma (NSCLC) is the most common type of lung cancer, accounting for 80% to 85% of lung cancer, and it shows a low proliferation rate and metastatic ability. Large-cell lung carcinoma accounts for 10% to 15% of NSCLC and is poorly differentiated [4, 5]. These tumors are large peripheral masses associated with early metastases. Surgery, radiotherapy, and chemotherapy are the main treatments for lung cancer. Although chemotherapy is the most common treatment for NSCLC [24, 6], NSCLC usually develops acquired resistance to chemotherapy and is associated with poor prognosis and low survival rates; therefore, continued efforts are still needed to overcome these difficulties [7, 8].

Aneuploidy is frequently observed in advanced cancer cells, and previous studies reported that at least 70% of common solid cancers are aneuploidy [911]. Cancer cells with aneuploidy may have enhanced proliferation and the ability to adapt to external stress or may be more chemoresistant [12]. A high rate of chromosomal missegregation has been reported to cause instability of chromosomes and poor prognosis in patients with diffuse large B cell lymphoma [13]. However, hyperaneuploidy beyond a certain level can be lethal or harmful to cancer cells [14, 15]. Therefore, elevating the rates of chromosome instability, such as aneuploidization or polyploidization, thereby inducing vulnerability of cancer cells to mitotic catastrophe [16] or apoptosis [14, 17], may be a promising strategy for treating cancer.

Phenoxyphenol derivatives have been reported to possess the capacity to prevent and treat colon and prostate cancers [18, 19]. Specifically, Parsai et al. reported that 4 phenoxyphenol derivatives exerted antimetastasis and anti-inflammatory activity by possibly binding to the active site of matrix metalloproteinase- (MMP-) 9 and cyclooxygenase (COX) 2 [20]. Additionally, we previously demonstrated that synthetic phenoxyphenol 4-[2356-tetrafluoro-4-(4-hydroxyphenoxy)phenoxy]phenol (TFPP) preconditioned NSCLC to respond to the anticancer agent camptothecin possibly by lowering the threshold for initiating apoptosis [21].

More recently, we identified that the synthetic phenoxyphenol 4-[4-(4-hydroxyphenoxy)phenoxy]phenol (4-HPPP) selectively killed hepatocellular carcinoma (HCC) cells and induced significant accumulation of γH2AX, a DNA damage sensor [22], through modulating autophagy and inducing apoptosis. However, the effect of 4-HPPP on other cancer cells and its underlying mechanism remain unclear.

Given the potential anti-HCC activity of 4-HPPP, we further tested whether 4-HPPP exerts inhibitory effects on NSCLC using in vitro and in vivo zebrafish-based xenograft assays. Furthermore, the possible mechanisms by which 4-HPPP induced increased reactive oxygen species (ROS) and modulated the threshold of polyploidy-specific cell death of NSCLC are discussed.

2. Materials and Methods

2.1. Source of Diphenoxy Benzene Compounds

Four diphenoxy benzene compounds, including 4-HPPP, were purchased from the Enamine Ltd. (http://www.enamine.net, Kyivska region, Ukraine) chemical database (REAL Database). Four diphenoxy benzene compounds were freshly dissolved in DMSO at a concentration of 10 mM and stored at -20°C, and concentrations of 0.5, 1, 5, and 10 μM were used to treat cells and zebrafish.

2.2. Cell Lines

The human NSCLC cell line H1299 was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), and the human bronchial epithelium cell line BEAS-2B was kindly provided by Dr. Poling-Kuo (Kaohsiung Medical University, Taiwan). All the tested cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM)/F-12 (3 : 2 ratio) and supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, and antibiotics (100 units/ml penicillin and 100 μg/ml streptomycin) at 37°C with a humidified atmosphere of 5% CO2.

2.3. Reagents

The following compounds were obtained from Gibco BRL (Gaithersburg, MD, USA): DMEM, FBS, trypan blue, penicillin G, and streptomycin. Dimethyl sulfoxide (DMSO), paraformaldehyde (#P6148), ribonuclease A (RNase A, #R-4642), and propidium iodide (PI) were purchased from Sigma-Aldrich (St. Louis, MO, USA). An annexin V-fluorescein isothiocyanate (FITC) staining kit was purchased from Strong Biotech (#AVK050, Taipei, Taiwan). 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzenedisulphonate (WST-1) was purchased from Takara Biomedicals (#MK400, Otsu, Japan). Antibodies against γH2AX (#sc-101696), phosphorylated Akt (Ser473, #sc-7985-R), phosphor-ATR (#sc-109912), and phosphor-ATM (#sc-47739) proteins were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Phosphor-Akt (Thr450, #3188-1) was purchased from Epitomics (Burlingame, CA, USA). Akt1 (#ab32505) was purchased from Abcam (Cambridge, UK). Bcl-2 (#GTX100064), peroxidase (PRX1) (#GTX101705), superoxide dismutase 1 (SOD1) (#GTX100659), SOD2 (#GTX116093), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (#GTX627408) were purchased from GeneTex (Irvine, CA, USA). DNA-dependent protein kinase (DNA-PK) (#556456) was purchased from BD Pharmingen™ (San Jose, CA, USA). Horseradish peroxidase- (HRP-) conjugated secondary antibodies (#20102 for goat anti-mouse IgG and #20202 for goat anti-rabbit IgG) were purchased from Leadgene Biomedical Inc., Tainan, Taiwan. Fluorescein isothiocyanate- (FITC-) conjugated secondary antibodies (#GTX26816 for goat anti-mouse IgG and #GTX26798 for goat anti-rabbit IgG) were purchased from GeneTex.

2.4. Colony Formation Assay

A total of H1299 cells were seeded onto a 6-well plate and then incubated for 24 h. The cells were treated with four diphenoxy benzene compounds at different concentrations (0, 0.5, 1, 5, and 10 μM). After 14 days of incubation, the cell colonies were fixed in glutaraldehyde and stained with crystal violet (1% /; Merck, #1408, Darmstadt, Germany) for 1 h. The diameter of the colonies was determined by Image-Pro Plus software (Media Cybernetics, Maryland, USA).

2.5. Cell Viability Assay

Cell viability was assessed by a WST-1 assay as described previously. Briefly, cells/well were seeded on a 96-well plate (tissue culture grade, flat bottom) in a final volume of 100 μl/well culture medium in a humidified atmosphere (37°C, 5% CO2); after 24 h, the cells were treated with different concentrations of Akt-target compounds (0, 0.5, 1, 5, and 10 μM) and cultured for 48 h. Next, 10 μl/well WST-1 reagent was added to each well, and cells were incubated for 30 minutes in a humidified atmosphere (37°C, 5% CO2). The absorbance of the samples was measured at 450 nm against the background of a blank control using a microplate (ELISA) reader (Multiskan Ascent 354 microplate reader, Thermo Fisher Scientific, Rockford, IL, USA).

2.6. Cell Cycle Distribution Assay

A total of cells were seeded on a 12-well plate. After 24 h, different concentrations of Akt-targeting compounds (0, 0.5, 1, 5, and 10 μM) were treated for 48, 72, and 96 h. The supernatant and cells were collected in a 1.5 ml tube, washed with PBS, fixed with 70% ethanol, and stored at -20°C for at least two hours. The ethanol was then removed, and the samples were washed with PBS and treated with Ribonuclease (RNase) A in 100 μl PBS (40 μg/ml) for 30 minutes. The RNase A was removed and washed with PBS, and the samples were treated with 20 μg/ml PI in PBS. The cells were analyzed by flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA, USA) using FlowJo 7.5.5 software (Tree Star, Inc., San Carlos, CA).

2.7. Assessment of Apoptosis

To examine the apoptosis-inducing potential of 4-HPPP in H1299 cells, annexin V/PI double staining was performed to detect the externalization of phosphatidylserine (PS). In brief, cells were seeded onto 12-well plates and treated with or without 4-HPPP for 48 h and 72 h. Subsequently, the cells were harvested and stained with the annexin V/PI kit (Strong Biotech) according to the manufacturer’s instructions. Cells were analyzed by flow cytometry (FACSCalibur) using FlowJo v7.5.5 software (Tree Star, Inc.).

2.8. Intracellular ROS Detection Assay

The amount of endogenous H2O2 was detected through an oxidation-sensitive fluorescence dye 2,7-dichlorofluorescein diacetate (DCF-DA). DCF-DA is able to penetrate the cell membrane. While entering the cell, it is cleaved and oxidized by H2O2 in cells, forming a DCF product with green fluorescence at wavelengths between 488 and 530 nm [2326]. Briefly, cells were seeded on a 12-well plate and treated with or without 4-HPPP for 24 h and 48 h. Afterward, cells were treated with different concentrations of 4-HPPP and its analogs (from 0.5 to 10 μM) for 24 h and 48 h. The supernatants were removed and washed with PBS, followed by the addition of 0.1 μM DCF-DA (2,7-dichlorofluorescein diacetate) (Sigma-Aldrich, St. Louis, Missouri, USA) to the 12-well plates for 30 minutes at 37°C. Then, the DCF-DA was removed, and the cells were washed with PBS. Cells were collected in 1.5 ml tubes and analyzed by flow cytometry (FACSCalibur) using FlowJo v7.5.5.

2.9. Cytometric Assessment of Protein Phosphorylation

DNA damage was analyzed in H1299 cells after 4-HPPP treatment by a flow cytometry-based assay to detect the activation of γH2AX, phosphor-ATM, phosphor-ATR, and DNA-PK in cells [27]. A total of cells were seeded on a 12-well plate and treated with or without 4-HPPP. After 24 h, cells were treated with the indicated concentrations (0, 0.5, 1, 5, and 10 μM) of 4-HPPP. Cells were harvested and washed with PBS and fixed with 70% ethanol at -20°C. The alcohol was removed, and cells were washed with BSA-T-PBS (1% BSA, 0.5% Triton in PBS), followed by the addition of γH2AX, phosphor-ATM, phosphor-ATR, or DNA-PK primary antibodies. The samples were then washed with BSA-T-PBS, and the fluorescent secondary antibody was added. Finally, the samples were washed with BSA-T-PBS and treated with 20 μg/ml PI in BSA-T-PBS. The cells were analyzed by flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA, USA) using FlowJo 7.5.5 software (Tree Star, Inc.).

2.10. Western Blot Analysis

Western blotting assays were conducted as described previously [28]. Briefly, the cells were harvested and lysed. Lysates were centrifuged, and the protein lysate concentrations were determined using a Pierce™ bicinchoninic acid (BCA) protein assay kit (#23225, Thermo Scientific Pierce Protein Research, Rockford, IL, USA). Equal amounts of protein (20 μg) were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and then electrotransferred to a 0.2 μm polyvinylidene difluoride (PVDF) membrane (Pall, FL, USA). The PVDF membrane was blocked with 5% nonfat milk and sequentially incubated with primary and secondary antibodies against specific proteins. The signal intensities were detected using an enhanced chemiluminescence (ECL) detection kit (Amersham, Piscataway, NJ, USA).

2.11. Cellular Motility Assessment

The cellular motility was determined using Boyden’s transwell assay. Briefly, H1299 cells were seeded on a transwell insert with 8 μm pore polycarbonate filters (Greiner Bio-One, Frickenhausen, Germany), and the lower well contained medium with 10% FBS without or with the indicated concentrations of 4-HPPP for 18 h. Cells on the bottom surface of the filters were paraformaldehyde-fixed and Giemsa-stained; then, all cells were counted under a microscope (Nikon Eclipse TE2000-U, Tokyo, Japan). The experiment was performed in triplicate, and the results of three independent experiments are presented as the .

2.12. Zebrafish Husbandry

Adult Tg(Fli1:GFP)y1 zebrafish were provided by the Zebrafish International Resource Center (ZIRC), Taiwan Zebrafish Core at National Health Institutes and Tsing Hua University (TZeTH), Hsinchu, Taiwan (http://icob.sinica.edu.tw/tzcas/fishlineszeth.html). Zebrafish were maintained in a 14 h light/10 h dark cycle at 28°C.

2.13. Toxicity in Zebrafish

Before the xenograft assay, the toxicity of 4-HPPP in zebrafish was tested by exposing zebrafish larvae at 2 days postfertilization (dpf) to 4-HPPP for 48 h. As toxicological endpoints, the images of abnormal larvae were recorded and calculated after 24 and 48 h of exposure.

2.14. Zebrafish Xenograft

To further validate the antilung cancer effect of 4-HPPP, we transfected the plasmid pDsRed-Express-C1 (Clontech, Mountain View, CA, USA) into human tumor cells for tracking the xenografted cells by fluorescence microscopy. The zebrafish-based xenograft assay was performed according to our previous study with minor modifications [29]. Briefly, 48 h postfertilization (hpf) zebrafish larvae were anesthetized with 0.01% tricaine and transplanted with approximately 50 lung cancer cells per larva by microinjection. The larvae were incubated in water with 4-HPPP for 24 h and 48 h postinjection. Afterward, images were captured with an inverted fluorescence microscope (Nikon Eclipse TE2000-U, Tokyo, Japan).

2.15. Statistical Analysis

Differences between 4-HPPP- and DMSO- (as vehicle control) treated cells were analyzed in at least triplicate experiments. The differences were analyzed by one-way analysis of variance (ANOVA) with considered significant. For the in vivo zebrafish xenograft assay, the metastasis potential was assessed by Fisher’s exact test according to the previous study of Tang et al. [30].

3. Results

3.1. 4-HPPP Reduces Colony Formation Capacity in NSCLC

Because 4-HPPP also belongs to the diphenoxy benzene family, we were interested whether other diphenoxy benzene compounds with different modifications could have cytotoxicity effects similar to those of 4-HPPP against cancer cells; the diphenoxy benzene compounds were obtained from the chemical company Enamine Ltd. (https://enamine.net/) and predicted to have Akt-targeting effects according to the bioinformatics approaches of Enamine Ltd. (Figure 1(a)). The results of the WST-1 assay showed that 4-HPPP moderately inhibited cell viability, but not in a dose-dependent manner (Figure S1). We then examined whether 4-HPPP reduced the clonogenicity of NSCLC cells, and a colony formation assay was conducted (Figure 1(b)). Interestingly, the results showed that 4-HPPP dramatically reduced the clonogenicity capacity of H1299 cells in a dose-dependent manner, suggesting a long-term inhibitory effect of 4-HPPP on the clonogenic capacity of NSCLC cells compared to that of other diphenoxy benzene compounds. Importantly, only a slight reduction in colony formation of 4-HPPP-treated normal lung bronchia BEAS-2B cells was observed (Figures 1(b) and 1(c)) compared with NSCLC cells, showing that the inhibitory effects of 4-HPPP were selective to NSCLC cells rather than normal lung cells.

3.2. 4-HPPP Induces Apoptosis in NSCLC Cells

As shown in Figures 2(a) and 2(b), the apoptosis of H1299 cells significantly increased at treatment concentrations of 5 and 10 μM. In addition, the Western blot results revealed that after 4-HPPP treatment, both the phosphorylation of prosurvival p-Akt (Ser473 and Thr450) and its downstream protein Bcl-2 were downregulated, whereas there were no significant changes in total Akt protein (Figure 3), suggesting that 4-HPPP regulates the activity of Akt rather than its protein level.

3.3. 4-HPPP Induces Polyploidy in NSCLC Cell Lines

To examine whether 4-HPPP induced NSCLC cell cycle disturbances, H1299 cells were treated with different concentrations of 4-HPPP (from 0.5 to 10 μM) for 48 and 72 h. The cells were then stained with PI to assess cell cycle distribution. The results showed that treatment with higher concentrations (5 and 10 μM) of 4-HPPP for 48 h significantly increased polyploidy or aneuploidy. After treatment for 72 h, the population of sub-G1, a hallmark of apoptosis, dramatically accumulated, suggesting that the induction of apoptosis by 4-HPPP is both dose- and time-dependent (Figures 4(a) and 4(b)).

3.4. 4-HPPP Induces DNA Damage of H1299

DNA damage is the major cause of aneuploidy or polyploidy in cancer cells [31, 32]. To determine whether 4-HPPP caused aneuploidy or polyploidy or triggered apoptosis in NSCLC cells, we conducted flow cytometry-based immunostaining and Western blotting to detect changes in the DNA damage sensor γH2AX (the phosphorylated form of the histone protein H2AX) [33]. The results showed that the fold of γH2AX-activated cells was increased by increasing the 4-HPPP concentration (Figures 5(a) and 5(b)). Consistently, the level of γH2AX was increased in a dose-dependent manner at 48 h post-4-HPPP treatment (Figure 5(c)). We also evaluated the distributions of foci of γH2AX in 4-HPPP-treated H1299 cells using immunofluorescence staining. Significant accumulation of γH2AX foci was detected in cells treated with 5 and 10 μM 4-HPPP (Figure 5(d)), indicating that 4-HPPP induced DNA damage, especially DNA double-strand breaks (DSBs), in H1299 cells.

To study whether markers of DNA damage were activated in 4-HPPP-treated cells, phosphor-ATM, phosphor-ATR, and DNA-PK were detected by flow cytometry. As shown in Figures 6(a) and 6(b), significantly more phosphor-ATR-positive cells were found than both ATM- and DNA-PK-positive cells, which revealed that 4-HPPP causes DNA damage, leading to ATR activation.

3.5. 4-HPPP Increased Hydrogen Peroxide Production

To determine whether 4-HPPP induces apoptosis through ROS, we detected intracellular hydrogen peroxide (H2O2), one of the major types of intracellular ROS, using flow cytometer-based DCF-DA staining. The results showed that 4-HPPP caused a dose-dependent increase in H2O2 (Figures 7(a) and 7(b)). Furthermore, Western blotting showed that the protein level of SOD2 was increased; in contrast, the peroxidase PRX1 was significantly decreased in a dose-dependent manner following 4-HPPP treatment (Figures 7(c) and 7(d)).

3.6. 4-HPPP Attenuates the Motility of NSCLC Cells

Figures 8(a) and 8(b) reveal that the motility of H1299 cells treated with the indicated concentrations of 4-HPPP at 0, 0.5, 1, 5, and 10 μM was , , , , and (), respectively, indicating that 4-HPPP attenuates motility, an index of metastasis of cancer in H1299 cells.

3.7. 4-HPPP Inhibits H1299 Cell Proliferation and Migration in Zebrafish Xenografts

Before evaluating the anticancer activity of 4-HPPP, we examined whether 4-HPPP causes side effects in zebrafish. The results showed that the survival rates of zebrafish larvae did not change below 1 μM 4-HPPP. However, the survival rate was only 42.2% after treatment with 5 μM 4-HPPP for 48 h (Figure 9(a)). The higher concentrations of 5 μM and 10 μM 4-HPPP caused slight bending of the body axes and edema in the zebrafish larvae (Figure 9(b)), indicating that a high concentration of 4-HPPP induced moderate side effects in zebrafish.

To further examine the anticancer effect of 4-HPPP in vivo, we generated a lung cancer xenograft zebrafish model by microinjection of fluorescent H1299 cells. Red fluorescent reporter H1299 cells were obtained by transfection with the pDsRed-Express-C1 vector (Figure 9(c)). Fluorescent images at 48 h posttreatment revealed a reduction in tumor volume and migration in 4-HPPP-treated xenografted H1299 cells (Figures 9(d) and 9(e)).

4. Discussion

It has been reported that most NSCLC cells with mutations and deletions of the tumor suppressor p53 are insensitive to anticancer drugs such as cisplatin [34]. In contrast, Akt signaling has been reported to be frequently overexpressed or dysregulated in NSCLC, resulting in the activation of the PI3K/Akt pathway, which inhibits apoptosis and is correlated with radioresistance [35]. Furthermore, Akt activity increases as cells progress through the G2/M phase [36]. Given that both p53 mutation and Akt overexpression are closely correlated with the chemoresistance and prognosis of NSCLC patients, Akt may play a pivotal role in NSCLC pathogenesis and, thus, represents an ideal target for therapeutic intervention.

We previously demonstrated that the synthetic phenoxyphenol 4-[4-(4-hydroxyphenoxy)phenoxy]phenol (4-HPPP) inhibits cellular proliferation and induces apoptosis in hepatocellular carcinoma cells [22]. In this study, we used H1299 cells, which carry null-p53 and constitutively active Akt, as a cell model to further examine the effect of 4-HPPP on NSCLC cells. First, we examined the effects of 4-HPPP and three structurally similar compounds (diphenoxy benzenes) on the viability and clonogenicity of H1299 cells. The results showed that among the tested compounds, 4-HPPP moderately inhibited the viability of NSCLC H1299 cells at 24 h and 48 h (Figure S1(a) and (b)). However, 4-HPPP had the most potential for inhibiting the colony formation of NSCLC cells (Figure 1), suggesting the long-term inhibitory effect of 4-HPPP on NSCLC cell clonogenicity. Importantly, 4-HPPP also preferentially inhibited colony formation in H1299 cells but not in BEAS-2B normal lung cells. The results suggested that the selective inhibitory effect of 4-HPPP may be a promising treatment in the future.

Our previous study showed that 4-HPPP potentially inhibits the phosphorylation of Akt at Ser473 and Thr450 in HCC Huh7 cells. Consistently, our results showed that 4-HPPP inhibited the activation of Akt in NSCLC H1299 cells (Figure 3). These observations confirmed that 4-HPPP could be a specific inhibitor of Akt, which may benefit the development of Akt-targeting drugs for treating cancer in the future.

We further assessed the cell cycle distribution after 4-HPPP treatment. The results revealed that 4-HPPP induced hyperaneuploidization of NSCLC cells in a dose-dependent manner (Figure 4). A recent study proposed that the induction of hyperaneuploidization or hyperpolyploidization can be considered beneficial for inducing the apoptosis of cancer cells that carry aneuploidy or polyploidy. For example, colorectal cancer cells with high polyploidy exhibited a positive response to cotreatment with irinotecan combined with 5-fluorouracil in a clinical trial [37].

We noted that 4-HPPP treatment caused S-phase cell accumulation at the 1 μM concentration, but this accumulation was decreased at 5 and 10 μM; moreover, the level of aneuploidy increased in a dose-dependent manner, suggesting the correlation of S-phase arrest and high-grade aneuploidization/polyploidization. Liu et al.’s work reported that a topoisomerase I inhibitor, a synthetic analog of camptothecin TCH-1030, caused S-phase arrest and finally resulted in polyploidization and sequentially apoptosis in a panel of breast cancer cell lines [38]. Their results suggested that TCH-1030 induces DNA damage and S-phase cell cycle arrest by impairing mitosis and cytokinesis, eventually leading to polyploidization (>4N) and apoptosis.

Another study also reported the correlation of sub-G1 cell cycle arrest and hyperpolyploidization. For example, Karna et al.’s work suggested that the novel microtubule-modulating noscapinoid EM011 dysregulates cell division and the asymmetric distribution of DNA, resulting in both high-grade polyploidy and sub-G1 cell accumulation, eventually causing tumor suppression and promoting death in breast cancer MCF-7 cells [39]. Similarly, our previous work revealed the antimicrotubule effect of 4-HPPP in HCC cells [22]; we noted that at 48 h, the 5 μM and 10 μM doses suddenly increased the number of cells in the sub-G1 phase, and aneuploidy increased simultaneously, suggesting that the accumulation of sub-G1 cells, a marker of apoptosis, might be caused by 4-HPPP-induced excess aneuploidization in H1299 cells. We further confirmed that 4-HPPP induces apoptosis in H1299 cells using annexin V staining (Figure 2). Thus, the above observations provide information about the mechanism underlying the S-phase cell arrest and sub-G1 cell increase induced by 4-HPPP treatment.

Earlier studies have indicated that polyploidy might be induced in cancer cells by severe DNA damage, especially DSBs [5, 6, 31, 40]. When cells are exposed to radiation or chemicals that cause DNA damage, DSBs are induced, and a subunit of histone, H2AX, is quickly phosphorylated at Ser139 to form γH2AX. Therefore, γH2AX is considered a marker of DNA damage [8, 33]. Our previous work demonstrated that 4-HPPP induces H2AX accumulation in HCC Huh7 and Ha22T cells [22]. In this study, to determine whether 4-HPPP causes polyploidization by inducing DNA damage in NSCLC cells, we analyzed γH2AX activation following 4-HPPP treatment (Figures 5(a) and 5(b)). The level of polyploidy induced by 4-HPPP was positively correlated with the activation of γH2AX in H1299 cells (Figures 5(c) and 5(d)). We also checked the activation of major DNA repair factors, including phosphor-ATM, phosphor-ATR, and DNA-PK, and the level of ATR activation was much higher than that of the other two factors following 4-HPPP treatment, suggesting that ATR may play a major role in the signaling of DNA damage (Figure 6).

Moderate levels of intracellular ROS, including hydroxyl radicals (OH), superoxide (O2-), and H2O2, are essential for the proliferation and survival of cells [41, 42]. ROS play an important role in signal transduction related to survival, proliferation, angiogenesis, and metastasis in cancer cells [4346]. However, excess ROS usually cause severe damage or apoptosis of cells, and upregulating endogenous ROS has been considered to be a promising strategy for eliminating cancer cells [4749]. Therefore, our results also demonstrated that 4-HPPP significantly increased endogenous ROS through modulating the expression of antioxidant enzymes such as SOD2 and peroxidase (Figures 7(a) and 7(b)).

Zebrafish (Danio rerio) is an excellent model for cancer research and drug discovery because of its rapid development and larval transparency [5052]. Zebrafish xenografts provide a unique opportunity to monitor the tumor-induced angiogenesis, growth, and invasiveness of xenografted tumor cells. In addition, zebrafish are also a useful tool for evaluating the effects of drugs and their side effect [22, 28, 53]. First, we evaluated the toxicity of 4-HPPP to the larvae of zebrafish; the survival rates of zebrafish larvae did not change at low concentrations of 4-HPPP (Figure 9). However, the results showed that a high concentration of 4-HPPP caused the zebrafish larval body axes to bend and develop edema, indicating that a high concentration of 4-HPPP could cause unfavorable side effects in zebrafish (Figure 9(a)); all the zebrafish larvae died at the highest concentration of 4-HPPP treatment.

The results of the in vivo zebrafish-based xenograft assay showed that both the tumor mass and cellular migration of xenografted H1299 cells were significantly attenuated following 4-HPPP treatment (Figures 9(c)9(e)), which is consistent with the in vitro results.

Accordingly, we thus suggest that 4-HPPP, a phenoxyphenol-based compound, could lead to DNA damage accumulation and increased ROS levels, resulting in γH2AX and ATR activation to induce excess aneuploidization/polyploidization, ultimately causing cell apoptosis. 4-HPPP, which also exhibits Akt-targeting properties, inhibited the activity of the phosphorylated sites of Akt, Ser473and Thr450, which are involved in both NSCLC cell proliferation and metastasis.

5. Conclusions

Our study demonstrated that 4-HPPP selectively inhibits the growth of NSCLC H1299 cells. We also confirmed that 4-HPPP significantly inhibits the activation of Akt but increases the levels of ROS, DNA damage, and hyperpolyploidy, finally inducing apoptosis in H1299 cells (Figure 10). In addition to its antiproliferative effects, 4-HPPP inhibits migration, a marker of metastasis in NSCLC cells; therefore, for the first time, we demonstrated the antimigration effect of 4-HPPP, which may benefit the development of antilung metastasis therapies. The potent inhibitory effect of 4-HPPP on the proliferation and metastasis of H1299 cells was validated by an in vivo zebrafish-based xenograft assay. However, we also noted that a higher concentration of 4-HPPP caused body axis deformation and edema in zebrafish larvae. The structure of 4-HPPP could be further modified and optimized to reduce its side effects for further application.

Data Availability

No data were used to support this study.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

This study was supported by the following grants: MOST106-2320-B-037-012, MOST106-2314-B-037-053-MY3, MOST107-2320-B-037-023, MOST107-2311-B-037-001, and MOST108-2314-B-037-051 from the Ministry of Science and Technology, Taiwan; #NSYSUKMU107-P002 and NSYSUKMU108-P021 from a National Sun Yat-sen University-KMU Joint Research Project, Taiwan; #108-CCH-KMU-002 and 108-CCH-KMU-003 from a Changhua Christian Hospital-KMU Joint Research Project, Taiwan; and KMUH106-6R36 and KMUH107-7R33 from the Kaohsiung Medical University Hospital (KMUH). We are grateful for the instrumental support for confocal microscopy, fluorescence resonance energy transfer microscopy, and flow cytometry provided by the Center for Research Resources and Development, Kaohsiung Medical University, Kaohsiung, Taiwan. We thank the Zebrafish Core Facility at Kaohsiung Medical University for the technical support.

Supplementary Materials

The inhibitory effect of 4-HPPP and its analogs on the short-term proliferation of NSCLC cells. H1299 cells were seeded and treated with the indicated concentrations of 4-HPPP or one of its analogs for 24 h (a) and 48 h (b). #1: 4-HPPP; #2: 4-[2356-tetrafluoro-4-(4-hydroxyphenoxy)phenoxy]phenol; #3: 4-[4-(4-aminophenoxy)-2356-tetrafluorophenoxy]aniline; and #4: 452 4-[4-(4-amino-3-nitrophenoxy)phenoxy]-2-nitroaniline. and , 4-HPPP compound treatments against vehicle control. (Supplementary Materials)

References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2018,” Ca: a Cancer Journal for Clinicians, vol. 68, no. 1, pp. 7–30, 2018. View at: Publisher Site | Google Scholar
  2. D. S. Ettinger, W. Akerley, G. Bepler et al., “Non-small cell lung cancer,” Journal of the National Comprehensive Cancer Network, vol. 8, no. 7, pp. 740–801, 2010. View at: Publisher Site | Google Scholar
  3. R. Pirker and W. Minar, “Chemotherapy of advanced non-small cell lung cancer,” Frontiers of Radiation Therapy and Oncology, vol. 42, pp. 157–163, 2010. View at: Publisher Site | Google Scholar
  4. L. G. Collins, C. Haines, R. Perkel, and R. E. Enck, “Lung cancer: diagnosis and management,” American Family Physician, vol. 75, no. 1, pp. 56–63, 2007. View at: Google Scholar
  5. R. Stupp, C. Monnerat, A. T. Turrisi 3rd, M. C. Perry, and S. Leyvraz, “Small cell lung cancer: state of the art and future perspectives,” Lung Cancer, vol. 45, no. 1, pp. 105–117, 2004. View at: Publisher Site | Google Scholar
  6. N. O'Rourke, I. F. M. Roque, N. Farre Bernado, and F. Macbeth, “Concurrent chemoradiotherapy in non-small cell lung cancer,” The Cochrane Database of Systematic Reviews, vol. 16, no. 6, article CD002140, 2010. View at: Google Scholar
  7. T. D. Wagner and G. Y. Yang, “The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC),” Current Drug Targets, vol. 11, no. 1, pp. 67–73, 2010. View at: Publisher Site | Google Scholar
  8. S. M. Keller, S. Adak, H. Wagner et al., “A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group,” The New England Journal of Medicine, vol. 343, no. 17, pp. 1217–1222, 2000. View at: Publisher Site | Google Scholar
  9. D. Cimini, “Merotelic kinetochore orientation, aneuploidy, and cancer,” Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, vol. 1786, no. 1, pp. 32–40, 2008. View at: Publisher Site | Google Scholar
  10. S. F. Bakhoum and D. A. Compton, “Chromosomal instability and cancer: a complex relationship with therapeutic potential,” The Journal of Clinical Investigation, vol. 122, no. 4, pp. 1138–1143, 2012. View at: Publisher Site | Google Scholar
  11. B. Orr, K. M. Godek, and D. Compton, “Aneuploidy,” Current Biology, vol. 25, no. 13, pp. R538–R542, 2015. View at: Publisher Site | Google Scholar
  12. M. Kawakami, X. Liu, and E. Dmitrovsky, “New cell cycle inhibitors target aneuploidy in cancer therapy,” Annual Review of Pharmacology and Toxicology, vol. 59, no. 1, pp. 361–377, 2019. View at: Publisher Site | Google Scholar
  13. S. F. Bakhoum, O. V. Danilova, P. Kaur, N. B. Levy, and D. A. Compton, “Chromosomal instability substantiates poor prognosis in patients with diffuse large B-cell lymphoma,” Clinical Cancer Research, vol. 17, no. 24, pp. 7704–7711, 2011. View at: Publisher Site | Google Scholar
  14. A. Glassmann, C. C. Garcia, V. Janzen et al., “Staurosporine induces the generation of polyploid giant cancer cells in non-small-cell lung carcinoma A549 cells,” Analytical Cellular Pathology, vol. 2018, Article ID 1754085, 7 pages, 2018. View at: Publisher Site | Google Scholar
  15. A. Datta and R. M. Brosh, “New insights into DNA helicases as druggable targets for cancer therapy,” Frontiers in Molecular Biosciences, vol. 5, no. 59, 2018. View at: Publisher Site | Google Scholar
  16. M. Giam and G. Rancati, “Aneuploidy and chromosomal instability in cancer: a jackpot to chaos,” Cell Division, vol. 10, no. 1, p. 3, 2015. View at: Publisher Site | Google Scholar
  17. R. Mirzayans, B. Andrais, and D. Murray, “Roles of polyploid/multinucleated giant cancer cells in metastasis and disease relapse following anticancer treatment,” Cancers, vol. 10, no. 4, p. 118, 2018. View at: Publisher Site | Google Scholar
  18. M. K. Kim, Y. J. Kang, D. H. Kim et al., “A novel hydroxamic acid derivative, MHY218, induces apoptosis and cell cycle arrest through downregulation of NF-κB in HCT116 human colon cancer cells,” International Journal of Oncology, vol. 44, no. 1, pp. 256–264, 2014. View at: Publisher Site | Google Scholar
  19. R. K. Lall, D. N. Syed, V. M. Adhami, M. I. Khan, and H. Mukhtar, “Dietary polyphenols in prevention and treatment of prostate cancer,” International Journal of Molecular Sciences, vol. 16, no. 2, pp. 3350–3376, 2015. View at: Publisher Site | Google Scholar
  20. S. Parsai, R. Keck, E. Skrzypczak-Jankun, and J. Jankun, “Analysis of the anticancer activity of curcuminoids, thiotryptophan and 4-phenoxyphenol derivatives,” Oncology Letters, vol. 7, no. 1, pp. 17–22, 2014. View at: Publisher Site | Google Scholar
  21. H. L. Chou, Y. Fong, C. K. Wei et al., “A quinone-containing compound enhances camptothecin-induced apoptosis of lung cancer through modulating endogenous ROS and ERK signaling,” Archivum Immunologiae et Therapiae Experimentalis, vol. 65, no. 3, pp. 241–252, 2017. View at: Publisher Site | Google Scholar
  22. W.-T. Chang, W. Liu, Y.-H. Chiu et al., “A 4-phenoxyphenol derivative exerts inhibitory effects on human hepatocellular carcinoma cells through regulating autophagy and apoptosis accompanied by downregulating α-tubulin expression,” Molecules, vol. 22, no. 5, p. 854, 2017. View at: Publisher Site | Google Scholar
  23. H. Hirai, H. Sootome, Y. Nakatsuru et al., “MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo,” Molecular Cancer Therapeutics, vol. 9, no. 7, pp. 1956–1967, 2010. View at: Publisher Site | Google Scholar
  24. J. K. Morrow, L. Du-Cuny, L. Chen et al., “Recent development of anticancer therapeutics targeting Akt,” Recent Patents on Anti-Cancer Drug Discovery, vol. 6, no. 1, pp. 146–159, 2011. View at: Publisher Site | Google Scholar
  25. H. S. Kang, H. Y. Chung, J. Y. Kim, B. W. Son, H. A. Jung, and J. S. Choi, “Inhibitory phlorotannins from the edible brown alga Ecklonia stolonifera on total reactive oxygen species (ROS) generation,” Archives of Pharmacal Research, vol. 27, no. 2, pp. 194–198, 2004. View at: Publisher Site | Google Scholar
  26. D. A. Bass, J. W. Parce, L. R. Dechatelet, P. Szejda, M. C. Seeds, and M. Thomas, “Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation,” Journal of Immunology, vol. 130, no. 4, pp. 1910–1917, 1983. View at: Google Scholar
  27. Z. Darzynkiewicz, D. H. Halicka, and T. Tanaka, “Cytometric assessment of DNA damage induced by DNA topoisomerase inhibitors,” Methods in Molecular Biology, vol. 582, pp. 145–153, 2009. View at: Publisher Site | Google Scholar
  28. A. Liu, H. Chen, W. Wei et al., “Antiproliferative and antimetastatic effects of emodin on human pancreatic cancer,” Oncology Reports, vol. 26, no. 1, pp. 81–89, 2011. View at: Publisher Site | Google Scholar
  29. C. H. Tzeng, Y. R. Chen, C. C. Tzeng et al., “Discovery of indeno[1,2-b]quinoxaline derivatives as potential anticancer agents,” European Journal of Medicinal Chemistry, vol. 108, pp. 258–273, 2016. View at: Publisher Site | Google Scholar
  30. Q. Tang, J. C. Moore, M. S. Ignatius et al., “Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish,” Nature Communications, vol. 7, no. 1, article 10358, 2016. View at: Publisher Site | Google Scholar
  31. I. Kikuchi, Y. Nakayama, T. Morinaga, Y. Fukumoto, and N. Yamaguchi, “A decrease in cyclin B1 levels leads to polyploidization in DNA damage‐induced senescence,” Cell Biology International, vol. 34, no. 6, pp. 645–653, 2010. View at: Publisher Site | Google Scholar
  32. M. B. Morelli, C. Amantini, M. Nabissi et al., “Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: the proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner,” Oncotarget, vol. 8, no. 2, pp. 3380–3395, 2017. View at: Publisher Site | Google Scholar
  33. V. Valdiglesias, S. Giunta, M. Fenech, M. Neri, and S. Bonassi, “γH2AX as a marker of DNA double strand breaks and genomic instability in human population studies,” Mutation Research, vol. 753, no. 1, pp. 24–40, 2013. View at: Publisher Site | Google Scholar
  34. B. G. Campling and W. S. El-Deiry, “Clinical implication of p53 mutation in lung cancer,” Molecular Biotechnology, vol. 24, no. 2, pp. 141–156, 2003. View at: Publisher Site | Google Scholar
  35. A. Chakravarti, G. Zhai, Y. Suzuki et al., “The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas,” Journal of Clinical Oncology, vol. 22, no. 10, pp. 1926–1933, 2004. View at: Publisher Site | Google Scholar
  36. E. Shtivelman, J. Sussman, and D. Stokoe, “A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle,” Current biology, vol. 12, no. 11, pp. 919–924, 2002. View at: Publisher Site | Google Scholar
  37. R. Bendardaf, H. Lamlum, R. Ristamäki, A. Ålgars, Y. Collan, and S. Pyrhönen, “Response to chemotherapy (irinotecan plus 5-fluorouracil) in colorectal carcinoma can be predicted by tumour DNA content,” Oncology, vol. 66, no. 1, pp. 46–52, 2004. View at: Publisher Site | Google Scholar
  38. Y.-P. Liu, H.-L. Chen, C.-C. Tzeng et al., “TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells,” Breast Cancer Research and Treatment, vol. 138, no. 2, pp. 383–393, 2013. View at: Publisher Site | Google Scholar
  39. P. Karna, P. C. G. Rida, V. Pannu et al., “A novel microtubule-modulating noscapinoid triggers apoptosis by inducing spindle multipolarity via centrosome amplification and declustering,” Cell Death and Differentiation, vol. 18, no. 4, pp. 632–644, 2011. View at: Publisher Site | Google Scholar
  40. T. R. Jackson, K. Salmina, A. Huna et al., “DNA damage causes TP53-dependent coupling of self-renewal and senescence pathways in embryonal carcinoma cells,” Cell Cycle, vol. 12, no. 3, pp. 430–441, 2013. View at: Publisher Site | Google Scholar
  41. H. Y. Fang, H. M. Wang, K. F. Chang et al., “Feruloyl-L-arabinose attenuates migration, invasion and production of reactive oxygen species in H1299 lung cancer cells,” Food and Chemical Toxicology, vol. 58, pp. 459–466, 2013. View at: Publisher Site | Google Scholar
  42. C. C. Chiu, H. L. Chou, P. F. Wu, H. L. Chen, H. M. Wang, and C. Y. Chen, “Bio-functional constituents from the stems of Liriodendron tulipifera,” Molecules, vol. 17, no. 4, pp. 4357–4372, 2012. View at: Publisher Site | Google Scholar
  43. A. Faissner, N. Heck, A. Dobbertin, and J. Garwood, “DSD-1-proteoglycan/phosphacan and receptor protein tyrosine phosphatase-beta isoforms during development and regeneration of neural tissues,” Advances in Experimental Medicine and Biology, vol. 557, pp. 25–53, 2006. View at: Publisher Site | Google Scholar
  44. C. Guo, A. V. Gasparian, Z. Zhuang et al., “9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-κB and p53 pathways,” Oncogene, vol. 28, no. 8, pp. 1151–1161, 2009. View at: Publisher Site | Google Scholar
  45. H. Pelicano, D. Carney, and P. Huang, “ROS stress in cancer cells and therapeutic implications,” Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, vol. 7, no. 2, pp. 97–110, 2004. View at: Publisher Site | Google Scholar
  46. D. Trachootham, J. Alexandre, and P. Huang, “Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?” Nature Reviews Drug Discovery, vol. 8, no. 7, pp. 579–591, 2009. View at: Publisher Site | Google Scholar
  47. B. R. Lee, S. Y. Chang, E. H. Hong et al., “Elevated endoplasmic reticulum stress reinforced immunosuppression in the tumor microenvironment via myeloid-derived suppressor cells,” Oncotarget, vol. 5, no. 23, pp. 12331–12345, 2014. View at: Publisher Site | Google Scholar
  48. J. C. Lee, M. F. Hou, H. W. Huang et al., “Marine algal natural products with anti-oxidative, anti-inflammatory, and anti-cancer properties,” Cancer Cell International, vol. 13, no. 1, p. 55, 2013. View at: Publisher Site | Google Scholar
  49. C. C. Chiu, J. W. Haung, F. R. Chang et al., “Golden berry-derived 4β-hydroxywithanolide E for selectively killing oral cancer cells by generating ROS, DNA damage, and apoptotic pathways,” PLoS One, vol. 8, no. 5, article e64739, 2013. View at: Publisher Site | Google Scholar
  50. J. Tat, M. Liu, and X. Y. Wen, “Zebrafish cancer and metastasis models for in vivo drug discovery,” Drug Discovery Today: Technologies, vol. 10, no. 1, pp. e83–e89, 2013. View at: Publisher Site | Google Scholar
  51. L. I. Zon and R. T. Peterson, “In vivo drug discovery in the zebrafish,” Nature Reviews Drug Discovery, vol. 4, no. 1, pp. 35–44, 2005. View at: Publisher Site | Google Scholar
  52. C. Chakraborty, C. H. Hsu, Z. H. Wen, C. S. Lin, and G. Agoramoorthy, “Zebrafish: a complete animal model for in vivo drug discovery and development,” Current Drug Metabolism, vol. 10, no. 2, pp. 116–124, 2009. View at: Publisher Site | Google Scholar
  53. C. C. Chiu, H. L. Chou, B. H. Chen et al., “BPIQ, a novel synthetic quinoline derivative, inhibits growth and induces mitochondrial apoptosis of lung cancer cells in vitro and in zebrafish xenograft model,” BMC Cancer, vol. 15, no. 1, 2015. View at: Publisher Site | Google Scholar

Copyright © 2020 Wangta Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views754
Downloads492
Citations

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.